NeoGenomics (NEO) Tops Q3 EPS by 3c, Beats on Revenues; Lifts FY18 EPS/Revenue Outlook Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. INTC
9. JBLU
10. HOOD

Go back to NeoGenomics (NEO) Tops Q3 EPS by 3c, Beats on Revenues; Lifts FY18 EPS/Revenue Outlook Above Consensus

NeoGenomics Reports 17% Revenue Growth to Record $69 Million

October 30, 2018 7:00 AM EDT

FT. MYERS, Fla., Oct. 30, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2018.

Third Quarter 2018 Highlights:

   17% increase in consolidated revenue 
   14% increase in clinical genetic testing volume(1)
   21% increase in Pharma Services revenue; 75% increase in Pharma Services backlog
   Completed $135 million, net equity offering
   Announced acquisition of Genoptix in October for $125 million in cash and 1 million shares of NeoGenomics common... More